{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:14Z","timestamp":1791378314834,"version":"4.3.2"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010896","name":"International Cooperation and Exchange Programme","doi-asserted-by":"publisher","award":["82272986"],"award-info":[{"award-number":["82272986"]}],"id":[{"id":"10.13039\/501100010896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.pharmthera.2022.108333","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T11:13:53Z","timestamp":1671016433000},"page":"108333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials"],"prefix":"10.1016","volume":"241","author":[{"given":"Jia","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin S.H.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0005","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/eji.200737590","article-title":"Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(\u2212) cells","volume":"38","author":"Aarts-Riemens","year":"2008","journal-title":"European Journal of Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jtcvs.2021.01.143","article-title":"The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases","volume":"163","author":"Antonoff","year":"2022","journal-title":"The Journal of Thoracic and Cardiovascular Surgery"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108333_bb0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13011","article-title":"From IPEX syndrome to FOXP3 mutation: A lesson on immune dysregulation","volume":"1417","author":"Bacchetta","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0025","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/cancers14071726","article-title":"Alternative splicing in cancer and immune cells","volume":"14","author":"Bernard","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0030","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.neo.2015.07.001","article-title":"Gli1-mediated regulation of Sox2 facilitates self-renewal of stem-like cells and confers resistance to EGFR inhibitors in non-small cell lung cancer","volume":"17","author":"Bora-Singhal","year":"2015","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0035","doi-asserted-by":"crossref","first-page":"11433","DOI":"10.2147\/OTT.S275649","article-title":"Expression profile of GINS complex predicts the prognosis of pancreatic cancer patients","volume":"13","author":"Bu","year":"2020","journal-title":"Oncotargets and Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer - from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nature Reviews. Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0050","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: Non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0055","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41590-019-0442-x","article-title":"Functional reprogramming of regulatory T cells in the absence of Foxp3","volume":"20","author":"Charbonnier","year":"2019","journal-title":"Nature Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0060","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cells8091015","article-title":"Long non-coding RNA in the pathogenesis of cancers","volume":"8","author":"Chi","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108333_bb0065","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.celrep.2019.03.066","article-title":"Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer","volume":"27","author":"Choi","year":"2019","journal-title":"Cell Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108333_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cei.13357","article-title":"Foxp3 in Treg cell biology: A molecular and structural perspective","volume":"199","author":"Deng","year":"2020","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.626172","article-title":"Post-translational regulations of Foxp3 in Treg cells and their therapeutic applications","volume":"12","author":"Dong","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108333_bb0080","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1634\/theoncologist.8-1-69","article-title":"Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer","volume":"8","author":"Ebert","year":"2003","journal-title":"The Oncologist"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108333_bb0090","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-07-5664","article-title":"The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells","volume":"68","author":"Ebert","year":"2008","journal-title":"Cancer Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108333_bb0095","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nature Reviews. Genetics"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108333_bb0100","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.celrep.2019.02.087","article-title":"Nemo-like kinase drives Foxp3 stability and is critical for maintenance of immune tolerance by regulatory T cells","volume":"26","author":"Fleskens","year":"2019","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050038","article-title":"Epigenetic control of the foxp3 locus in regulatory T cells","volume":"5","author":"Floess","year":"2007","journal-title":"PLoS Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.acthis.2012.06.002","article-title":"Foxp3 and TLR4 protein expression are correlated in non-small cell lung cancer: Implications for tumor progression and escape","volume":"115","author":"Fu","year":"2013","journal-title":"Acta Histochemica"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662840","article-title":"Radiation resistance: A matter of transcription factors","volume":"11","author":"Galeaz","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0120","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1186\/s12885-020-07324-z","article-title":"Fut4sirna augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000491670","article-title":"Foxo1 inhibits tumor cell migration via regulating cell surface morphology in non-small cell lung cancer cells","volume":"48","author":"Gao","year":"2018","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108333_bb0130","first-page":"1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2022.108333_bb0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/01902148.2019.1617371","article-title":"Foxp3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma","volume":"45","author":"Giatromanolaki","year":"2019","journal-title":"Experimental Lung Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108333_bb0140","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1159\/000517490","article-title":"Ki67 as proliferative marker in patients with early breast cancer and its association with clinicopathological factors","volume":"99","author":"de Gregorio","year":"2021","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0145","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41379-019-0260-6","article-title":"Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome","volume":"32","author":"Hammarsten","year":"2019","journal-title":"Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Seminars in Cancer Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0155","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.immuni.2017.07.008","article-title":"Analyses of a mutant Foxp3 allele reveal BATF as a critical transcription factor in the differentiation and accumulation of tissue regulatory T cells","volume":"47","author":"Hayatsu","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.gene.2013.08.066","article-title":"Foxp3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population","volume":"531","author":"He","year":"2013","journal-title":"Gene"},{"issue":"7689","key":"10.1016\/j.pharmthera.2022.108333_bb0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb1000","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.tig.2020.11.003","article-title":"Forkhead Transcription Factors in Health and Disease","volume":"37","author":"Herman","year":"2021","journal-title":"Trends in Genetics: TIG"},{"issue":"5609","key":"10.1016\/j.pharmthera.2022.108333_bb0170","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0175","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.21037\/tcr.2019.12.60","article-title":"A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib","volume":"9","author":"Huang","year":"2020","journal-title":"Translational Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbcan.2018.12.004","article-title":"The expression of FOXP3 and its role in human cancers","volume":"1871","author":"Jia","year":"2019","journal-title":"Biochimica Et Biophysica Acta. Reviews on Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0185","first-page":"167","article-title":"Foxp3 expression in A549 cells is regulated by toll-like receptor 4 through nuclear factor-\u03baB","volume":"6","author":"Jia","year":"2012","journal-title":"Molecular Medicine Reports"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0190","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.18632\/aging.101897","article-title":"Alternative splicing, FOXP3 and cardiovascular disease","volume":"11","author":"Joly","year":"2019","journal-title":"Aging"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0195","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.biocel.2010.07.015","article-title":"Signalling through FOXP3 as an X-linked tumor suppressor","volume":"42","author":"Katoh","year":"2010","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0200","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-016-1825-6","article-title":"Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation","volume":"65","author":"Ke","year":"2016","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0205","doi-asserted-by":"crossref","first-page":"18994","DOI":"10.1038\/s41598-020-76130-1","article-title":"Regulatory (FoxP3+) T cells and TGF-\u03b2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Koh","year":"2020","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0210","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc1692","article-title":"The role of autophagy in cancer development and response to therapy","volume":"5","author":"Kondo","year":"2005","journal-title":"Nature Reviews. Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108333_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061479","article-title":"Targeting transcription factors for cancer treatment","volume":"23","author":"Lambert","year":"2018","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108333_bb0225","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.prp.2017.09.004","article-title":"Downregulation of FOXP3 inhibits cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma","volume":"213","author":"Li","year":"2017","journal-title":"Pathology, Research and Practice"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108333_bb0230","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3892\/etm.2021.10390","article-title":"Foxp3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1\/Hes1 pathway","volume":"22","author":"Li","year":"2021","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0235","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3892\/mmr.2012.1066","article-title":"Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells","volume":"6","author":"Li","year":"2012","journal-title":"Molecular Medicine Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024827","article-title":"Expression and prognosis analysis of GINS subunits in human breast cancer","volume":"100","author":"Li","year":"2021","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110124","article-title":"Control of Foxp3 induction and maintenance by sequential histone acetylation and DNA demethylation","volume":"37","author":"Li","year":"2021","journal-title":"Cell Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0250","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3892\/mmr.2014.2680","article-title":"Role of transcription factor FOXA1 in non-small cell lung cancer","volume":"17","author":"Li","year":"2018","journal-title":"Molecular Medicine Reports"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108333_bb0255","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1038\/s41388-021-01816-3","article-title":"Malat1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0260","article-title":"Gins1 induced sorafenib resistance by promoting cancer stem properties in human hepatocellular cancer cells","volume":"9","author":"Li","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108333_bb0265","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1007\/s13277-015-4616-3","article-title":"Overexpression of the transcription factor FOXP3 in lung adenocarcinoma sustains malignant character by promoting G1\/S transition gene CCND1","volume":"37","author":"Li","year":"2016","journal-title":"Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0270","doi-asserted-by":"crossref","first-page":"4534080","DOI":"10.1155\/2022\/4534080","article-title":"Foxp3 contributes to TMZ resistance, prognosis, and immune infiltration in GBM from a novel pyroptosis-associated risk signature","volume":"2022","author":"Liang","year":"2022","journal-title":"Disease Markers"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0275","first-page":"4081","article-title":"Oxymatrine-mediated maturation of dendritic cells leads to activation of FOXP3+\/CD4+ Treg cells and reversal of cisplatin-resistance in lung cancer cells","volume":"19","author":"Liu","year":"2019","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0280","article-title":"Pd-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108333_bb0285","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI131335","article-title":"Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer","volume":"130","author":"Liu","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108333_bb0290","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.18632\/aging.101918","article-title":"Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma","volume":"11","author":"Liu","year":"2019","journal-title":"Aging"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108333_bb0295","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2217\/fon.12.26","article-title":"Inactivation of X-linked tumor suppressor genes in human cancer","volume":"8","author":"Liu","year":"2012","journal-title":"Future Oncology (London, England)"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0300","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fonc.2013.00294","article-title":"Searching for the achilles heel of FOXP3","volume":"3","author":"Lozano","year":"2013","journal-title":"Frontiers in Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0305","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nature Reviews. Immunology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108333_bb0310","first-page":"4957","article-title":"Gli1, a potential cancer stem cell marker, is strongly associated with prognosis in prostate cancer","volume":"11","author":"Lv","year":"2018","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108333_bb0315","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cac2.12229","article-title":"The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation","volume":"41","author":"Ma","year":"2021","journal-title":"Cancer Communications"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clim.2018.03.008","article-title":"Ipex due to an exon 7 skipping FOXP3 mutation with autoimmune diabetes mellitus cured by selective TReg cell engraftment","volume":"191","author":"Magg","year":"2018","journal-title":"Clinical Immunology (Orlando, Fla.)"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0325","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fimmu.2018.00530","article-title":"Alternative splicing of FOXP3-virtue and vice","volume":"9","author":"Mailer","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006104","article-title":"Absence of leucine zipper in the natural FOXP3Delta2Delta7 isoform does not affect dimerization but abrogates suppressive capacity","volume":"4","author":"Mailer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0335","article-title":"Advances in systemic therapy for non-small cell lung cancer","volume":"375","author":"Miller","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108333_bb0340","first-page":"5860","article-title":"The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells","volume":"17","author":"Peng","year":"2018","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0345","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/bs.vh.2017.05.007","article-title":"Roles of thyroid transcription factor 1 in lung cancer biology","volume":"106","author":"Phelps","year":"2018","journal-title":"Vitamins and Hormones"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0350","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ni.3812","article-title":"Mll4 prepares the enhancer landscape for Foxp3 induction via chromatin looping","volume":"18","author":"Placek","year":"2017","journal-title":"Nature Immunology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108333_bb0355","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/eji.200838105","article-title":"Dna methylation controls Foxp3 gene expression","volume":"38","author":"Polansky","year":"2008","journal-title":"European Journal of Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0360","first-page":"51","article-title":"Transient receptor potential vanilloid 4 promotes the growth of non-small cell lung cancer by regulating Foxp3","volume":"69","author":"Pu","year":"2022","journal-title":"Acta Biochimica Polonica"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0365","first-page":"1839","article-title":"Glioma-associated oncogene homolog 1 stimulates FOXP3 to promote non-small cell lung cancer stemness","volume":"12","author":"Qi","year":"2020","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0370","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919855228","article-title":"Egfr-AS1\/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancer","volume":"11","author":"Qi","year":"2019","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers"},{"issue":"10066","key":"10.1016\/j.pharmthera.2022.108333_bb0380","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: Current therapies and new targeted treatments","volume":"389","author":"Scagliotti","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0385","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s12885-017-3633-6","article-title":"Foxp3 is a HCC suppressor gene and acts through regulating the TGF-\u03b2\/Smad2\/3 signaling pathway","volume":"17","author":"Shi","year":"2017","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0390","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/JTO.0b013e3181d60fd7","article-title":"Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer","volume":"5","author":"Shimizu","year":"2010","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0395","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0400","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0405","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12957-021-02268-5","article-title":"Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma","volume":"19","author":"Song","year":"2021","journal-title":"World Journal of Surgical Oncology"},{"issue":"43","key":"10.1016\/j.pharmthera.2022.108333_bb0410","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Science Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108333_bb0415","first-page":"209","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0420","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10753-016-0470-8","article-title":"Foxp3, regulatory T cell, and autoimmune diseases","volume":"40","author":"Tao","year":"2017","journal-title":"Inflammation"},{"issue":"10299","key":"10.1016\/j.pharmthera.2022.108333_bb0425","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0430","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jcp.24125","article-title":"Foxp3 expression in tumor cells and implications for cancer progression","volume":"228","author":"Triulzi","year":"2013","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108333_bb2000","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2022.05.001","article-title":"Smarca4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils","volume":"169","author":"Velut","year":"2022","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108333_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111400","article-title":"Forkhead box protein P3 (FOXP3) represses ATF3 transcriptional activity","volume":"22","author":"Wang","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072036","article-title":"Foxp3 activates SUMO-conjugating UBC9 gene in MCF7 breast cancer cells","volume":"19","author":"Wang","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0445","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pharmthera.2017.08.003","article-title":"Members of FOX family could be drug targets of cancers","volume":"181","author":"Wang","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0450","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1038\/s41418-019-0304-y","article-title":"Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Death and Differentiation"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0455","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.ymthe.2018.06.015","article-title":"Microrna-125b interacts with Foxp3 to induce autophagy in thyroid cancer","volume":"26","author":"Wang","year":"2018","journal-title":"Molecular Therapy\u202f: The Journal of the American Society of Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153003","article-title":"Hippo pathway and tumoral FOXP3 expression correlate with tumor growth in squamous cell carcinoma of the lung","volume":"216","author":"Won","year":"2020","journal-title":"Pathology, Research and Practice"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0465","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3892\/ol.2021.12672","article-title":"Expression and prognostic value of E2F3 transcription factor in non-small cell lung cancer","volume":"21","author":"Wu","year":"2021","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153742","article-title":"Cochlioquinone derivative CoB1 induces cytostatic autophagy in lung cancer through miRNA-125b and Foxp3","volume":"93","author":"Xu","year":"2021","journal-title":"Phytomedicine : International Journal of Phytotherapy and Phytopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0475","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12943-017-0700-1","article-title":"Foxp3 promotes tumor growth and metastasis by activating Wnt\/\u03b2-catenin signaling pathway and EMT in non-small cell lung cancer","volume":"16","author":"Yang","year":"2017","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0480","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fonc.2018.00631","article-title":"Oxymatrine and cisplatin synergistically enhance anti-tumor immunity of CD8+ T cells in non-small cell lung cancer","volume":"8","author":"Ye","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108333_bb0485","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2020.06.005","article-title":"Ube2t promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation","volume":"494","author":"Yin","year":"2020","journal-title":"Cancer Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108333_bb0490","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41388-018-0482-y","article-title":"Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer","volume":"38","author":"Yochum","year":"2019","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108333_bb0495","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-15-2581","article-title":"Biased expression of the FOXP3\u03943 isoform in aggressive bladder cancer mediates differentiation and cisplatin chemotherapy resistance","volume":"22","author":"Zhang","year":"2016","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108333_bb0500","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21739","article-title":"Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)","volume":"41","author":"Zhang","year":"2021","journal-title":"Medicinal Research Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108333_bb0505","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41416-020-0825-7","article-title":"Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1","volume":"122","author":"Zhao","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108333_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113024","article-title":"Foxp3 activated-LINC01232 accelerates the stemness of non-small cell lung carcinoma by activating TGF-\u03b2 signaling pathway and recruiting IGF2BP2 to stabilize TGFBR1","volume":"413","author":"Zhu","year":"2022","journal-title":"Experimental Cell Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108333_bb0515","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/1759-7714.12795","article-title":"Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases","volume":"9","author":"Zhu","year":"2018","journal-title":"Thoracic Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108333_bb0520","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cell.2007.04.034","article-title":"Foxp3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2\/ErbB2 oncogene","volume":"129","author":"Zuo","year":"2007","journal-title":"Cell"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822002273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822002273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:31:01Z","timestamp":1759012261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822002273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":106,"alternative-id":["S0163725822002273"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108333","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108333"}}